TSHA - NASDAQ
Taysha Gene Therapies, Inc.
$5.55
-2.5%Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
At a Glance
Live SnapshotTaysha Gene Therapies, Inc. Management Team
Mr. Sean McAuliffe
Chief Business Officer
Mr. Sean P. Nolan
Chief Executive Officer & Chairman
Compensation
$1,031,634
Mr. Kamran Alam CPA, M.B.A.
Chief Financial Officer & Corporate Secretary
Compensation
$676,688
Berge Minassian M.D.
Chief Medical Advisor of UT Southwestern Gene Therapy Program
Ms. Emily McGinnis M.P.H.
Chief Patient & External Affairs Officer
Ms. Tracy M. Porter SPHR
Chief People Officer
Dr. Steven Gray Ph.D.
Chief Scientific Advisor of UT Southwestern Gene Therapy Program
Mr. Frederick Porter Ph.D.
Chief of Staff & Technical Operations Officer
Hayleigh Collins
Director of Corporate Communications & Investor Relations
Dr. Sukumar Nagendran M.D.
President, Head of Research & Development and Director
Compensation
$907,175
Taysha Gene Therapies, Inc. Insider Positioning
During the last 12 months, insiders have purchased $29K and sold $5.41M worth of TSHA shares, resulting in $5.38M of net selling activity.
3 Months
0
0.00
200.0K
892.00K
-892K
-$892K
3-6 Months
0
0.00
598.6K
2.82M
-2.8M
-$2.82M
6-9 Months
41.1K
28.76K
370.2K
1.70M
-1.7M
-$1.67M
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Nagendran Sukumar
Director, Officer: President And Head Of R&D
$29K
Top Sellers
Nagendran Sukumar
Director, Officer: President And Head Of R&D
$4.08M
Nolan Sean P.
Director, Officer: Chief Executive Officer
$840K
Alam Kamran
Officer: Chief Financial Officer
$493K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $5.38M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
3 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
TSHA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 22, 2026 | June 01, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 21, 2025 | June 02, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 18, 2024 | May 29, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | October 05, 2023 | November 15, 2023 | 2023 | |
DEF 14A DEF 14A 2023 N/A | May 08, 2023 | June 22, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 28, 2022 | June 17, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 29, 2021 | June 17, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.